Alexion Uses Excess Cash To Buy Strikingly Similar Synageva
This article was originally published in The Pink Sheet Daily
Executive Summary
At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.
You may also be interested in...
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Ulta Beauty Leadership Offers 2023 Holiday Outlook, AI Update In Q3 Earnings Call
The US’ biggest beauty retailer is targeting fiscal 2023 net sales between $11.1bn and $11.15bn, with comparable sales growth of 5% to 5.5%, and is optimistic about 2024 and longer-term strategies. CEO David Kimbell addressed analyst questions on the 2023 holiday season, AI and other points of interest during the firm’s third-quarter earnings call.
Pharmative Sitting Out Trendy Spin-Off Dance
"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.